Understanding patient and physician responses to various cost-sharing programs for prescription drugs in South Korea: A multilevel analysis
Patient and/or physician responses are a pivotal issue in designing rational cost-sharing programs under health insurance systems. This study aims to understand patient and/or physician responses to cost-sharing programs designed for prescription drugs in South Korea. As a framework, we took advanta...
Gespeichert in:
Veröffentlicht in: | Frontiers in public health 2022-08, Vol.10, p.924992-924992 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Patient and/or physician responses are a pivotal issue in designing rational cost-sharing programs under health insurance systems.
This study aims to understand patient and/or physician responses to cost-sharing programs designed for prescription drugs in South Korea.
As a framework, we took advantage of a tiered cost-sharing program, including from copayment to coinsurance (threshold 1) and reduced coinsurance (threshold 2). Given the hierarchical structure of prescriptions nested within patients, we utilized a multilevel analysis to assess effects of various cost-sharing programs on patient and/or physician responses using National Health Insurance claims data from 2018.
We found that a tiered cost-sharing program was effective in changing the behaviors of patients and/or physicians. Threshold 1 was found to be more effective than threshold 2 in changing their behaviors. At the prescription level, sensitivity to cost-sharing programs was associated with prescribed days of treatment and locations of prescription. In a similar vein, sensitivity to cost-sharing programs was associated with gender and age group of patients.
A simplified cost-sharing program with extended intervals should be considered to rationalize cost-sharing programs. Specifically, a cost-sharing program designed for long-term prescriptions for chronic diseases together with an emphasis on cost transparency is required to better guide price-conscious decisions by patients and/or physicians. |
---|---|
ISSN: | 2296-2565 2296-2565 |
DOI: | 10.3389/fpubh.2022.924992 |